Study of Docetaxel followed by FEC as primary systemic chemotherapy for operable breast cancer (JBCRG-03)

Study of Docetaxel followed by FEC as primary systemic chemotherapy for operable breast cancer (JBCRG-03) - JBCRG-03(DOC-FEC as primary systemic chemotherapy)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000291

Enrollment

130

Registered

2005-11-25

Start date

2005-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Operable breast cancer

Interventions

Chemotherapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: T1c-3N0M0, T1-3N1M0 No previous treatment for breast cancer Adequate organ function Written informed consent

Exclusion criteria

Exclusion criteria: Drug hypersensitivity Severe complication Inflammatory breast cancer Double cancer Bilateral breast cancer

Design outcomes

Primary

Measure	Time frame
Pathological responce, safety	—

Secondary

Measure	Time frame
Clinical response, Breast conserving rate, Overall survival, Disease free survival	—

Countries

Japan

Contacts

Public ContactKatsumasa Kuroi

JBCRG Head office

office@jbcrg.jp03-6264-8873

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026